Prime Medicine, Inc.

The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir

Metabolic disease alliances have picked up as companies try to find a spot in the growing obesity market, and earlier this decade the COVID-19 pandemic drove a short-lived uptick in infectious disea

In Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo

In the top alliance by deal value, Prime Medicine and Bristol Myers Squibb teamed up to develop reagents for multiple next-generation, ex vivo CAR-T cell therapies in immunology and oncology. Prime